Feb 26, 2021 in Press Releases

Xphyto provides updated comments on promotional and marketing activity

VANCOUVER, British Columbia – February 26, 2021 – XPhyto Therapeutics Corp. (CSE: XPHY; OTC: XPHYF; FSE: 4XT) (“XPhyto” or the “Company”) at the request of IIROC and the Canadian Securities Exchange (the “CSE”) is providing additional comments to its news release and list of third-party providers dated January 22, 2021 with regards to recent promotional and investor relations activity (“Promotional Activity”) provided by said third-parties, in particular a newsletter published by WallStreetAlerts, on behalf of the Company.

The Company reminds investors that the best source for full disclosure about the company is the company itself, SEDAR or CSE profile pages for regulatory filings and news releases. The Company acknowledges that prior to the date of this news release, XPhyto did not comply with the CSE requirements to complete and post Form 10 Notices of Proposed Significant Transactions disclosing its contracts with the third-party providers. The Company has now completed and posted the required forms to the CSE and will continue to do so in the future.
The Company will adopt a public disclosure policy to establish and formalize processes for approval of any communications that could be considered Promotional Activity conducted on behalf of the Company in order to ensure that such communications are not false, inaccurate, overly promotional, or misleading and include adequate and accurate information for investors to assess risk and make informed investment decisions. Under the public disclosure policy, all communications to be circulated by a person engaged in Promotional Activities will require approval by a committee of the Company’s board of directors and legal advisors prior to publication.

The Company has attached to this news release (Schedule A) a list of the third parties who provided Promotional Activities on behalf of the Company over the past twelve months. Over such time period, the Company has provided compensation in the amount of $4,936,892 to such service providers. For further information related to each contract, please refer to the Form 10 filings under the Company’s profile on the CSE website, www.thecse.com.

The Company does not make any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 pandemic. Further, its COVID-19 related test products are not yet approved and are still subject to risks associated with the regulatory approval process.

Schedule A

Third Party Provider within last 12 monthsDate First engagedCurrently Active
Accesswire Canada Ltd.Sept-19Y
Agora Internet Relations Corp.Dec-20Y
BullVestor Medien GmbHMar-20N
Cayo Ventures GmbHJul-19Y
Digitonic Ltd.Mar-20N
Emerging Markets LLCFeb-21Y
Equity Guru Media Inc.Jun-20Y
ex-cubed GmbHMay-19Y
Inside International Media GmbHMar-20N
InvestorIntel Corp.Aug-20N
Investing Channel, Inc.Jan-21Y
IR-World.com Finanzkommuikation GmbHApr-19Y
JG Business Management LLCSep-20Y
Knox Communications Inc.Jul-20Y
Link MediaFeb-21N
Loud Media & Awareness GmbHMar-20N
M. Davis & Associates Capital Inc.Apr-19Y
MC Services AGAug-20Y

Media Inquiries
E: info@bionxt.com